# Bio-Hykon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bio-hykon

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.biohykon.com
- Latest round: Series A (Jul 24, 2018)
- Investors on record: 1

## About

Based in Shanghai, China, and founded in 2014, Bio-Hykon operates as a medical reagent and instrument manufacturer, dedicated to the research, development, and production of in vitro diagnostic reagents and instruments. The company was recognized as a Shanghai High-Tech Enterprise and Shanghai New Venture Enterprise. It also has set up a production base as well as a subsidiary in Jiangsu. In July 2016, Bio-Hykon raised angel funding from new investor Shanghai Litong Venture Capital Co., LTD. In October 2017, it closed pre-A funding from new investor DAAN Gene. In July 2018, the company completed series A funding from new investor Guodu Venture Capital.

Bio-Hykon is dedicated to the research, development, and production of cancer diagnostic reagents based on circulating tumor cells (CTCs) and supporting instruments. Its main products are the Breast Cancer Circulating Tumor Cell Detection Kit and the Microfluidic Multicolor Fluorescent Cell Counter. The company also developed CTC test products for other tumors such as colorectal cancer, liver cancer, lung cancer, and glioma.

## Funding rounds

- Series A, Jul 24, 2018 — Guodu Venture Capital

## Investors

- Guodu Venture Capital (https://capitalatlas.ai/funds/guodu-venture-capital) — Series A